The EASO this year has the organization of the 14th European Congress on Obesity (ECO 2005.

The EASO this year has the organization of the 14th European Congress on Obesity (ECO 2005, to be held in Athens, 4 October 2005, 4 October 2005, to the Hellenic Medical Association for Obesity (assigned to Congress under the auspices organized by the Ministry of Health and Social Affairs, the city of Athens, Athens Medical School and the National Council and the University of Athens. For more information, visit the conference website.

The Investigational New Drug application will be transferred to Merck, and Merck will the global application for approval oncology indications oncology indications and lead all interactions with regulatory agencies. – This amended agreement positions Merck and ARIAD to the therapeutic potential of ridaforolimus by evaluating its properties in several cancer types and promotes Merck’s commitment to cancer research and promoting the health of people who maximize to cancer, said Muna Bhanji, senior Vice President and General Manager, Oncology Franchise at Merck.Effect anastrozole on bone and fractures: Results The from the ‘ Arimidex ” , Tamoxifen, itself or at combining trial.European J. Cancer Supplements 2004; 2 : 140, par two hundred eighty-nine. Which big ATAC Trialists’ Group. Impact of anastrozole and tamoxifen as adjuvant treatment on early-stage breast cancer, and 100 – months analysis ATAC study. The Lancet Oncology, 2008, 9 45-53. Fulvestrant SmPC for. Robertson JF, Osborne CK, Howell A et al. Fulvestrant is versus to anastrozole for to treatment of advanced breast cancer postmenopausal women. Cancer 2003, 98 : 229-238. Fulvestrant, formerly ICI the one hundred and eighty second be as effective as Arimidex in postmenopausal women with advanced breast cancer the Progressing by ago Endocrine Treatment 9.

Other entries from category "reports":

Tag Cloud